Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Seta Shahin"'
Autor:
Brenda J. Crowe, Seta Shahin, Melvin Munsaka, Mary E. Nilsson, Wei Wang, Greg Ball, Greg Anglin
Publikováno v:
Statistics in Biopharmaceutical Research
article-version (VoR) Version of Record
article-version (VoR) Version of Record
In this paper, we provide guidance on how standard safety analyses and reporting of clinical trial safety data may need to be modified, given the potential impact of the COVID-19 pandemic. The impact could include missed visits, alternative methods f
Autor:
Komal Jhaveri, David M. Hyman, Richard Bryce, Melanie E. Dujka, Sarina Anne Piha-Paul, David I. Quinn, Ingrid A. Mayer, Cristina Saura, David B. Solit, Gary A. Ulaner, Seta Shahin, Ben Stone, Grace Mann, Funda Meric-Bernstam
Publikováno v:
Clin Cancer Res
Purpose: To determine whether FDG PET can expand eligibility in biomarker-selected clinical trials by providing a means to quantitate response in patients with non-assessable disease by RECIST. Experimental Design: SUMMIT (NCT01953926) is a multicent
Publikováno v:
Therapeutic Innovation & Regulatory Science. 49:398-404
Safety assessment and monitoring are critical throughout the life cycle of drug development. The evaluation of safety information, specifically adverse events, from clinical trials has always been challenging for a number of reasons, such as the unex
Autor:
Lyndah Dreiling, Chandra P. Belani, Lee S. Schwartzberg, Seta Shahin, Warren S. Paroly, Howard A. Burris, Alan N. Gordon, Alan Saven, Peter A. Kaufman
Publikováno v:
Journal of Oncology Practice. 6:133-140
To compare data on severe (grade 4) neutropenia duration and febrile neutropenia incidence in patients receiving chemotherapy with pegfilgrastim administered the same day or 24 hours after chemotherapy.These were similar, randomized, double-blind pha
Autor:
Robert Deeter, David R. Spigel, Carroll Scroggin, Philip J. Stella, Edith P. Mitchell, Rafael G. Amado, Christopher Hagenstad, Seta Shahin, Tarek Chidiac, David McCollum, Allen Lee Cohn, J. Randolph Hecht, John Marshall
Publikováno v:
Journal of Clinical Oncology. 27:672-680
Purpose Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irino
Publikováno v:
Supportive cancer therapy. 2(4)
A metaanalysis of 4 clinical studies that treated adult solid tumors with standard combination chemotherapy and growth factor support was conducted to study average relative dose intensity. All studies compared pegfilgrastim with filgrastim in a rand
Autor:
Seta Shahin, Hafez Al-Halawani, Jennifer Tam, Veena Charu, Lodovico Balducci, William B. Ershler, Lyndah Dreiling
Publikováno v:
The oncologist. 12(12)
Background. There is a misconception that elderly cancer patients cannot tolerate standard doses of chemotherapy because of the frequency and severity of myelosuppressive complications. The reactive use of colony-stimulating factors (i.e., in respons
Autor:
Edward J. Campbell, Frank Norton, Seta Shahin, Jack L. Clausen, Mark L. Brantly, Raed A. Dweik, James K. Stoller, James M. Stocks, Farshid N. Rouhani
Publikováno v:
Chest. 122(1)
Augmentation therapy with pooled human plasma-derived alpha(1)-antitrypsin (AAT) has been shown to have biochemical efficacy in restoring serum AAT levels above the protective threshold. Also, clinical efficacy has been suggested.To evaluate the bioe
Autor:
Jeannette Green, Lodovico Balducci, Roger Dansey, Seta Shahin, Veena Charu, Jennifer Tam, William B. Ershler, Ali Ben-Jacob
Publikováno v:
Blood. 106:4286-4286
Introduction: Although non-Hodgkin’s lymphoma (NHL) is frequently diagnosed in older patients, few randomized clinical trials are conducted in this setting. Furthermore, older patients who are included in clinical studies are a highly selected grou